T2 Biosystems Inc (TTOO) Options

Yes. The Huge Book Value of that NASDAQ Bio-Tech peer is 4.6 Times of its Ridiculous-Low Bottom price! So, it is Super Undervalued now! Also, it is at Hyper Oversold status --- from 12/30/2024's Daily-High $10.4 to the New 52-week-low $1.18! So, it will be Very Easy for that Hidden Gem to Surge over its most recent high $3.35 (on 01/28/2025, the Pre-Market-Session-High)!

TTOO is Almost CH7-Bankrupt Already! Why do you want to buy it? I'm not buying the Pos Scam unless the price crashes to Below $0.01! I just want to warn any potential TTOO investor's Huge Downward Risks and also advise all the existing TTOO shareholders: how to recover their Huge Losses from buying TTOO by investing in a Super Good NASDAQ Bio-Tech stock at current Basement price levels!

It looks like the company is done and over with. This employee says the doors are shut and the game is over

CRG will most likely strip the products and patents out of the company and make use of them elsewhere. Great products and tech with dogshit management is a recipe for failure I believe that's what you have here. 

Key to TTOO is that it has the POTENTIAL
to be the Standard of Care for the testing they
are involved with.

The problem is, the 'established' ones making money
doing the testing, are going to lose this source of income.
Not to mention anyone else that is currently getting a piece
of the 'money' pie.

But IF its that much better, that much more efficient without
sacrificing the quality of the results?

It SHOULD win, but its going to take TIME for it to happen.

Cause the status quo is going to resist change. Especially
if it costs them money. For anyone believing effectiveness
and efficiency for the patients is the priority of the health care
system? When it comes to money?? LOL...

VINC is running PHASE 1 trials. Just did a reverse split..

So WHY again would you want to be buying this one that is
going to be bleeding cash for a few more years?

I don't disagree with you at all. This stock is a huge piece of shit And a very poorly run company. Technology and the patents are good but that doesn't mean shit when everything else around it is garbage.

Unfortunately, with respect to what the institutions are doing, they don't have to
report their trading until forget how many days after a qtr ends. So by the time you
can read about it, to a degree, its old 'news'

Yet suspect the share price activity will reflect some of that in the next several days.

TTOO: re institution holdings, most institutions have articles against holding common shares of an OTC security. Shareholders would need to contact the company to know if institutional holders of T2 Biosystems Inc needed or need to liquidate their holdings.

Check this link frequently to see if institutions are selling (or sold) their holdings:

https://www.nasdaq.com/market-activity/stocks/ttoo/institutional-holdings

14.5 Mil shares exchanged hands today. Not bad for a float of
around 28 Mil, supposedly with 73% of them held by 'institutions'.

Was chatting with someone this afternoon and mentioned, going to
be interesting to see what that institutional holding number does
due them dropping off the major exchange to a sub tier one.

IE, will some of the institutions be forced to sell their holdings because
of the de-listing (honestly don't know, never thought about it before this)

disclaimer: I am out, but will see where this settles down. They are
going to vote on the possibility of a r/split. And they indicate they will
keep filing their SEC docs which to me indicates, they are planning to
get uplisted again. Plus I like what they are trying to do.

Good luck, and yeah, it hurt a bit to sell since I got in at 23 cents..only good news is,
I hadn't loaded up cause I was waiting for the chart to say, the market is starting to increase
demand for the shares.

TTOO delisted from the Nasdaq to the OTC. ***pps dropped 36% from .19 to .125 on ~15 million volume.

https://otce.finra.org/otce/dailyList?viewType=Additions

Agree on the phenomenal products. And that the OTC listing
is NOT the end of the road.

Just going to get out of the way and see what happens to the share price
next.

It is my favorite type of 'play' when it comes to investing in something. Can the
product dominate vs the established.

It sure looks like it should be able to, will just take some more time..

disclaimer: only owned shares since late Jan.. so not a lot of history with them

This is not uncommon.TTOO has phenomenal technology and products. I have seen many companies that have great products and shit management that go down this path. My feeling is that crg is going to take over the patents and replace management and run it themselves. The OTC d listing is not the end of the story it's just a major bump in the road. If they regroup and run the corporate end properly the technology and products will be put to good use if not it will just all go to shit and their patents and technology will be sold off or taken over by somebody else.

Call this a first for me, first time I have had one delisting in over
25 years of trading.

And the interesting part is, there was something they could have done
to stay listed, but they chose not to.. (aka, sell shares to raise cash, then
do that r/split that they are asking for a vote on: aka, I expect they will
execute that dilution/r/split down the road).

Still like what they are doing, so while I just sold out cause not sure whats
going to happen next? I still see them becoming the standard of care for
what they claim to be capable of diagnosing...

So I will continue to monitor them, and expect to take a position again when
the dust settles. UGH

PS: thanks for the heads up cause I just looked thru their 'PR' listings and
presentation last night and didn't see it

https://investors.t2biosystems.com/node/13411/html

Care to provide a link to 'de-listing'??

Delisting is rough. I'm curious to see what CRG is going to do now. 

Naw, its not unfortunate unless you have some news to report.

I stay focused on the END GAME.. what happens along
the way could present an opportunity or two..

Sorry mate. Thats unfortunate. 

Blub blub blub...game over. 

This has to hold 18 or it's going to see 13.

Looks good enough to grab a starter @ .20

Found out that TTOO sent out letters to shareholders
of record around Jan 6th asking for a vote for
permission to conduct a r/split IF needed, of a
size between 1-10 to 1-100 in what appears to
be a 'tool' to keep themselves listed.

There is an SEC filing on their website detailing
the request for a proxy vote, and why.

But with only 28 Mil shares available and the
institutions reportedly holding 73% of the shares
already? Won't surprise me if they do a r/split
and then sell some shares.

I don't really have a target price on them at the moment.
But told someone, assume they can justify a MARKET CAP of
$200 Million for starters. WIth 28 Mil shares, thats a target price of
approx $7/sh. So the r/split is not what I am concerned about, it
will be the selling of shares to raise cash. So assume they
double up the share count, at todays share price, and
say 56 Mil shares, the target price would be $3.50 or so.

Still be a heck of a nice return from 24 cents to $3 or so..
To me, the MARKET CAP they can justify is the key to what
I can forcast for a target price. Helps they have a low share
count and being able to buy in cheap to boot..

have to see where this one goes in the next 6 months..

Ok I'll accept that 👍👍 good. 

Well, they appear to be ok there as well.

Did a 1-50 back in late 2022, a 1-100 in Oct 2023

So the 2 year window would include Jan 2023 till today..

Like TNXP, (up for an FDA decision in Aug), TTOO appears to be able
to at least try to justify requesting an extension given they have an approved
device and are working to expand its usage as a means to 'anticipate' a rise
in the share price.

I really don't want to see a R/split being used. And on TTOO with only 28 mil
shares outstanding?? Market cap of less than $7 Mil?? It would get quite
interesting if they did even a 1-5 to get to a $ (less than 6 Mil shares) and have a
good qtrly report..

This is my concern. 

An amendment to Nasdaq Listing Rule 5810(c)(3)(A)(iv) included in the 17 January 2025 rule changes provides that an issuer is not eligible for any compliance period to cure a deficiency under the minimum bid price requirement if it has effected a reverse stock split over the prior one-year period. This change follows another recent amendment to Rule 5810(c)(3)(A)(iv), effective in 2020, not allowing a compliance period in the event the issuer has effected one or more reverse stock splits with a cumulative ratio of 250 shares or more to one during the two-year period preceding noncompliance with the minimum bid price requirement. Any issuer that receives a delisting determination under these circumstances can appeal for a hearing before a Nasdaq panel (during which time the suspension of trading of its securities will be stayed).

Actually, what it looks like according below is:
-companies can still APPEAL the initial de-listing warning, get a 180 day extension. Which I would fully
expect any company to do. Especially if they are on the verge of seeing a ramp up in revenues/sales
which based on the Nov CC, the CEO says they are 'expecting' to see (revenues projected to be up, and
they are pushing for increased sales thanks to actions like aligning with Cardinal Health).

and on the R/split, they CAN do one if the last one was done at least a year earlier... No??


https://natlawreview.com/article/state-play-reverse-stock-splits-nasdaq-and-nyse-listed-issuers
Nasdaq Stock Market Rules
A Nasdaq-listed issuer’s primary equity security must maintain a minimum bid price of US$1.00. If the trading price of a primary equity security closes under US$1.00 per share for 30 consecutive business days, the issuer will generally have 180 days to regain compliance with the minimum bid price requirement. At the end of the 180-day compliance period, the issuer can be granted an additional 180-day compliance period by notifying Nasdaq of its intent to cure the deficiency, including by effecting a reverse stock split. Prior to recent rule changes, if the issuer had not cured the minimum bid price deficiency by the end of the second compliance period, it could appeal delisting of its stock by requesting a review by a hearings panel. Such a request would automatically stay any suspension or delisting action, up to an additional 180 days, pending the hearing and the expiration of any additional compliance period granted by the hearings panel following the hearing. Under the prior Nasdaq rules, it was possible for a company to be out of compliance with the bid price requirement for 540 days, or approximately 18 months, if all the possible compliance periods were exhausted.

Removal of Stay Period After Second 180-Day Compliance Period
Nasdaq’s most recent rule change relating to reverse stock splits was approved by the US Securities and Exchange Commission (SEC) on 17 January 2025. Under the new Nasdaq Listing Rule 5815(a)(1)(B)(ii)d, when an issuer has been afforded a second 180-day compliance period and does not regain compliance by the bid price of its stock closing at US$1.00 per share or greater for a minimum of 10 consecutive business days prior to the end of the second 180-day period, a request for a hearing no longer stays the suspension and delisting of the security pending the Nasdaq panel’s decision. Instead, effective upon the expiration of the second 180-day compliance period, trading of the issuer’s securities on Nasdaq will be automatically suspended and move to the over-the-counter (OTC) market while any appeal is pending.

Reduced Availability of Compliance Periods for Use of Multiple Reverse Splits
An amendment to Nasdaq Listing Rule 5810(c)(3)(A)(iv) included in the 17 January 2025 rule changes provides that an issuer is not eligible for any compliance period to cure a deficiency under the minimum bid price requirement if it has effected a reverse stock split over the prior one-year period. This change follows another recent amendment to Rule 5810(c)(3)(A)(iv), effective in 2020, not allowing a compliance period in the event the issuer has effected one or more reverse stock splits with a cumulative ratio of 250 shares or more to one during the two-year period preceding noncompliance with the minimum bid price requirement. Any issuer that receives a delisting determination under these circumstances can appeal for a hearing before a Nasdaq panel (during which time the suspension of trading of its securities will be stayed).

They will a big reverse..max. New rules state if they fall below 1.00 after RS they can't do another. Forces companies to max RS for price protection. 

All comes down to their MARKET CAP. Currently at $7 MIL.

And with 28 Mil shares outstanding, SP 23 cents?? Needing a $?

Maybe at the most a 1-5?

can't make float too small or it will be very volatile. Just have to hope
they don't sell shares but given their cash status, won't be surprised if
they do. Damn... didn't see this..

Thought they would ask for an extension to see how things went first..

Took a position today at 23 cents. Not a heavy one, chart is still
indecisive in terms of where it goes next.

But really liked the webcast of their Nov 2024 CC. Question is, can they
break thru the current SOC protocol with what they claim is a much better/faster
diagnostic 'tool'...

Plan to add more if it drops lower, or at 24-25 and I see a change ihe market
sentiment towards them in their chart.

Good luck..

TTOO...2534...🥳...Off my .26 Alert...

georgie18

Member Level
Re: georgie18 post# 5832

Tuesday, January 21, 2025 7:22:09 AM

Post#
5833
of 5838
TTOO...286...🥳...on this Oversold Bottom...

georgie18

Member Level
Re: None

Saturday, January 18, 2025 12:42:24 PM

Post#
671765
of 671806
TTOO...26...🥳... https://schrts.co/wkTpqqTF ...Bullish Meeting Line Reversal Pattern...13 Million Range Float...Post 1/100 Reverse Split on Oct 23,2024...

Achieved record product revenues of $2.3 million for the fourth quarter of 2024 and $8.3 million for the full-year 2024, representing increases of 37% and 23% respectively, compared to the prior year period, driven by record sepsis test sales.
Executed contracts for 27 T2Dx® Instruments in 2024, including 23 T2Dx Instruments for outside the U.S. and 4 T2Dx Instruments for the U.S.
Entered into a multi-year exclusive U.S. agreement with Cardinal Health, granting Cardinal exclusive rights to sell the T2Dx Instrument, the T2Bacteria Panel, and the T2Candida® Panel, the only FDA-cleared products able to detect sepsis-causing pathogens directly-from-blood.
Announced co-marketing collaboration with Prxcision, to market the Company’s rapid direct-from-blood diagnostics with Prxcision’s real-time AI-powered decision support platform to combat the escalating crisis of antibiotic resistance.
Expanded international distribution network to include the Netherlands, Belgium, Qatar, Vietnam, Malaysia, and Indonesia, and re-entered Switzerland.
Extended multi-year capital equipment supplier agreement with Vizient, Inc., the largest member-driven health care performance improvement company in the US, through March 31, 2026.
Converted $30 million of the Company’s term loan with entities affiliated with CRG Servicing, LLC (“CRG”) into T2 Biosystems’ common stock, reducing the Company’s debt and quarterly interest payments by approximately 80% over the past year.
Cash and cash equivalents were $1.7 million as of December 31, 2024.

Yup 6 weeks...could have 3 or 4 runs till then...🥳...I'm holding...

Quite a ways off.

Thanks...🥳

DEF 14A (Proxy statement) filed yesterday. R/S to be voted on in March
Notice is hereby given that a special meeting (the “Special Meeting”) of stockholders of T2 Biosystems, Inc. (the “Company”) will be held on March 3, 2025, at 9 a.m., Eastern time. The Special Meeting will be held by means of remote communications, which will be conducted via live webcast on the Internet, providing a consistent experience to stockholders regardless of location. You will be able to attend the meeting online, vote your shares electronically and submit your questions during the Special Meeting by visiting www.virtualshareholdermeeting.com/TTOO2025SM. There will not be a physical meeting, and you will not be able to physically attend the Special Meeting. Details regarding how to participate in the meeting online and the business to be conducted at the Special Meeting are more fully described in the enclosed proxy statement and the document appended thereto.

The Special Meeting will be held for the following purpose:



1.
To approve an amendment to the Company’s certificate of incorporation to effect a reverse stock split of the Company’s common stock, par value $0.001 per share (the “Common Stock”) at a reverse split ratio ranging from any whole number between and including 1-for-10 and 1-for-100, with the exact ratio within such range to be chosen at the discretion of the Board of Directors, subject to the Board of Directors’ authority to abandon the amendment.

Another RS? LOL...The CEO should be jailed

TTOO...286...🥳...on this Oversold Bottom...

georgie18

Member Level
Re: None

Saturday, January 18, 2025 12:42:24 PM

Post#
671765
of 671806
TTOO...26...🥳... https://schrts.co/wkTpqqTF ...Bullish Meeting Line Reversal Pattern...13 Million Range Float...Post 1/100 Reverse Split on Oct 23,2024...

Achieved record product revenues of $2.3 million for the fourth quarter of 2024 and $8.3 million for the full-year 2024, representing increases of 37% and 23% respectively, compared to the prior year period, driven by record sepsis test sales.
Executed contracts for 27 T2Dx® Instruments in 2024, including 23 T2Dx Instruments for outside the U.S. and 4 T2Dx Instruments for the U.S.
Entered into a multi-year exclusive U.S. agreement with Cardinal Health, granting Cardinal exclusive rights to sell the T2Dx Instrument, the T2Bacteria Panel, and the T2Candida® Panel, the only FDA-cleared products able to detect sepsis-causing pathogens directly-from-blood.
Announced co-marketing collaboration with Prxcision, to market the Company’s rapid direct-from-blood diagnostics with Prxcision’s real-time AI-powered decision support platform to combat the escalating crisis of antibiotic resistance.
Expanded international distribution network to include the Netherlands, Belgium, Qatar, Vietnam, Malaysia, and Indonesia, and re-entered Switzerland.
Extended multi-year capital equipment supplier agreement with Vizient, Inc., the largest member-driven health care performance improvement company in the US, through March 31, 2026.
Converted $30 million of the Company’s term loan with entities affiliated with CRG Servicing, LLC (“CRG”) into T2 Biosystems’ common stock, reducing the Company’s debt and quarterly interest payments by approximately 80% over the past year.
Cash and cash equivalents were $1.7 million as of December 31, 2024.

TTOO...26...🥳... https://schrts.co/wkTpqqTF ...Bullish Meeting Line Reversal Pattern...13 Million Range Float...Post 1/100 Reverse Split on Oct 23,2024...

Achieved record product revenues of $2.3 million for the fourth quarter of 2024 and $8.3 million for the full-year 2024, representing increases of 37% and 23% respectively, compared to the prior year period, driven by record sepsis test sales.
Executed contracts for 27 T2Dx® Instruments in 2024, including 23 T2Dx Instruments for outside the U.S. and 4 T2Dx Instruments for the U.S.
Entered into a multi-year exclusive U.S. agreement with Cardinal Health, granting Cardinal exclusive rights to sell the T2Dx Instrument, the T2Bacteria Panel, and the T2Candida® Panel, the only FDA-cleared products able to detect sepsis-causing pathogens directly-from-blood.
Announced co-marketing collaboration with Prxcision, to market the Company’s rapid direct-from-blood diagnostics with Prxcision’s real-time AI-powered decision support platform to combat the escalating crisis of antibiotic resistance.
Expanded international distribution network to include the Netherlands, Belgium, Qatar, Vietnam, Malaysia, and Indonesia, and re-entered Switzerland.
Extended multi-year capital equipment supplier agreement with Vizient, Inc., the largest member-driven health care performance improvement company in the US, through March 31, 2026.
Converted $30 million of the Company’s term loan with entities affiliated with CRG Servicing, LLC (“CRG”) into T2 Biosystems’ common stock, reducing the Company’s debt and quarterly interest payments by approximately 80% over the past year.
Cash and cash equivalents were $1.7 million as of December 31, 2024.

CEO is a thug imo. What a clown. I feel bad for anyone sucker into buying this stock.

There it is ... reverse split of 1 to 10, or 1 to 100.

Better than you think 

Reverse split to stay listed likely.

Check .5574 for a real disaster.

.75 + 10% check $1.08'for a real breakout 

TTOO, new 52 week low

TTOO, new 52 week low

Added.92s 

TTOO anew 52+week low

$1.14s added some dipping nicely

$1.30s the new bottom could see some action now